Suppr超能文献

用于经皮闭合卵圆孔未闭的新型生物可吸收间隔修复植入物:单中心经验的短期结果

New bioabsorbable septal repair implant for percutaneous closure of a patent foramen ovale: short-term results of a single-centre experience.

作者信息

Van den Branden B J L, Post M C, Jaarsma W, ten Berg J M, Suttorp M J

机构信息

Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands.

出版信息

Catheter Cardiovasc Interv. 2009 Aug 1;74(2):286-90. doi: 10.1002/ccd.21998.

Abstract

BACKGROUND

Permanent implants for closure of a patent foramen ovale (PFO) have a number of possible disadvantages including erosions, thrombus formation, and allergic reactions. The incidence of adverse events may be lower using a bioabsorbable device.

OBJECTIVE

To evaluate the short-term safety and efficacy of a new bioabsorbable closure device.

METHODS

All 35 consecutive patients (21 female, mean age 47.9 +/- 10.8 years), who underwent a percutaneous PFO closure between November 2007 and July 2008, were included. All complications were reported. The efficacy was based on the residual shunting the day after implant and at 1 month follow-up and was graded as minimal, moderate, or severe, using contrast transthoracic echocardiography with the Valsalva manoeuvre.

RESULTS

The only in-hospital complication was a surgical device retrieval from the femoral vein. Four patients developed a minimal inguinal haematoma. One day after closure, residual shunting was present in 56% of the patients (minimal 27%, moderate 23% and severe 6%). At 1 month follow-up (n = 33), one patient developed a transient neurological deficit and three patients suffered from paroxysmal atrial fibrillation. A residual shunt at 1 month was present in 45% of the patients (minimal 30%, moderate 12%, and severe 3%).

CONCLUSIONS

Percutaneous PFO closure using the bioabsorbable closure device seems to be safe. However, a high rate of residual shunting is present at 1 month follow-up. Long-term follow-up data are necessary to evaluate the efficacy and safety of this device.

摘要

背景

用于闭合卵圆孔未闭(PFO)的永久性植入物存在一些潜在缺点,包括侵蚀、血栓形成和过敏反应。使用生物可吸收装置时不良事件的发生率可能较低。

目的

评估一种新型生物可吸收闭合装置的短期安全性和有效性。

方法

纳入2007年11月至2008年7月间连续接受经皮PFO闭合术的所有35例患者(21例女性,平均年龄47.9±10.8岁)。报告所有并发症。疗效基于植入后次日及1个月随访时的残余分流情况,采用Valsalva动作经胸超声心动图检查,并分为微量、中度或重度。

结果

唯一的院内并发症是从股静脉取出手术装置。4例患者出现微量腹股沟血肿。闭合术后1天,56%的患者存在残余分流(微量27%,中度23%,重度6%)。在1个月随访时(n = 33),1例患者出现短暂性神经功能缺损,3例患者发生阵发性心房颤动。1个月时45%的患者存在残余分流(微量30%,中度12%,重度3%)。

结论

使用生物可吸收闭合装置经皮闭合PFO似乎是安全的。然而,在1个月随访时存在较高比例的残余分流。需要长期随访数据来评估该装置的有效性和安全性。

相似文献

2
Patent foramen ovale closure using a bioabsorbable closure device: safety and efficacy at 6-month follow-up.
JACC Cardiovasc Interv. 2010 Sep;3(9):968-73. doi: 10.1016/j.jcin.2010.06.012.
4
Safety and performance of the Spider™ patent foramen ovale occluder.
Catheter Cardiovasc Interv. 2013 Feb;81(2):317-23. doi: 10.1002/ccd.24584. Epub 2012 Sep 28.
5
The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
Catheter Cardiovasc Interv. 2015 May;85(6):1058-65. doi: 10.1002/ccd.25750. Epub 2014 Nov 27.
6
Percutaneous patent foramen ovale closure using the Occlutech Figulla device: More than 1,300 patient-years of follow up.
Catheter Cardiovasc Interv. 2019 May 1;93(6):1080-1084. doi: 10.1002/ccd.27984. Epub 2018 Nov 20.
7
Figulla PFO occluder versus Amplatzer PFO occluder for percutaneous closure of patent foramen ovale.
Catheter Cardiovasc Interv. 2011 Apr 1;77(5):709-14. doi: 10.1002/ccd.22737. Epub 2010 Oct 7.
8
Residual Shunt after Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data.
J Stroke Cerebrovasc Dis. 2019 Feb;28(2):347-353. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.006. Epub 2018 Nov 3.
10
Comparison of residual shunt rate and complications across 6 different closure devices for patent foramen ovale.
Catheter Cardiovasc Interv. 2020 Feb 15;95(3):365-372. doi: 10.1002/ccd.28527. Epub 2019 Oct 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验